Evidence map›Paper›PMID 29551008›Full record

ArticleDermatology and therapy2018

Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.

Sebastian Spindeldreher, Bernard Maillère, Evelyne Correia, Maxime Tenon, Anette Karle, Philip Jarvis, Frank Kolbinger

Abstract readPublished Erratum
In one paragraph

Article in Dermatology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Sebastian SpindeldreherNovartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Sebastian.Spindeldreher@novartis.com.
Bernard MaillèreCEA-Saclay, Institut Frédéric Joliot, SIMOPRO, Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Evelyne CorreiaCEA-Saclay, Institut Frédéric Joliot, SIMOPRO, Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Maxime TenonCEA-Saclay, Institut Frédéric Joliot, SIMOPRO, Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Anette KarleIntegrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Novartis Pharma AG, Basel, Switzerland.
Philip JarvisNovartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
Frank KolbingerNovartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication, information regarding "ustekinumab" was incorrectly published under the Methods section. The correct information in the section "Antibodies and Control Protein" should be "(secukinumab, 150 mg/mL; ixekizumab, 90 mg/mL; adalimumab, 50 mg/mL; ustekinumab 90 mg/ml)". Infliximab, which is mentioned in that section, was not used in the study.

Identifiers

PMID29551008
PMCPMC6002311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.